Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction

Published:2022-11 Issue: Volume:73 Page:117001
ISSN:0968-0896
Container-title:Bioorganic & Medicinal Chemistry
language:en
Short-container-title:Bioorganic & Medicinal Chemistry

Author:

Sasmal Pujan,Kumar Babasahib Sajeev,Prashantha Kumar B.R.,Manjunathaiah Raghavendra Nulgumnalli

Funder

Rajiv Gandhi University of Health Sciences

Indian Council of Medical Research

All India Council for Technical Education

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference128 articles.

1. Cancer immunoediting: from immunosurveillance to tumor escape;Dunn;Nat Immunol,2002

2. Cancer-related inflammation;Mantovani;Nature,2008

3. Immunity, inflammation, and cancer;Grivennikov;Cell,2010

4. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity;Shankaran;Nature,2001

5. Adaptive immunity maintains occult cancer in an equilibrium state;Koebel;Nature,2007

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthesis and immunotherapy efficacy of a PD-L1 small-molecule inhibitor combined with its 131I-iodide labelled isostructural compound;Bioorganic Chemistry;2024-12

2. Design, synthesis, anti-tumor activity and mechanism of novel PROTACs as degraders of PD-L1 and inhibitors of PD-1/PD-L1 interaction;Bioorganic & Medicinal Chemistry;2024-09

3. An updated patent review on PD-1/PD-L1 antagonists (2022-present);Expert Opinion on Therapeutic Patents;2024-06-25

4. Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges;Frontiers in Immunology;2024-04-10

5. Reducing PD-L1 Expression by Degraders and Downregulators as a Novel Strategy to Target the PD-1/PD-L1 Pathway;Journal of Medicinal Chemistry;2024-04-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3